Promising novel cytotoxic agents and combinations in metastatic prostate cancer

Deborah A. Bradley; Maha Hussain

doi:10.1097/PPO.0b013e31816220b7

Promising novel cytotoxic agents and combinations in metastatic prostate cancer

Deborah A. Bradley, Maha Hussain^*

^*Corresponding author for this work

Medicine, Hematology Oncology Division

Research output: Contribution to journal › Review article › peer-review

16 Scopus citations

Abstract

Interest in investigating cytotoxic therapy has increased dramatically since a survival advantage was demonstrated in 2 phase III trials investigating docetaxel-based therapy in hormone-refractory prostate cancer. This result led to an expansion in research in this area with several ongoing trials evaluating docetaxel-based combinations and new cytotoxic agents.

Original language	English (US)
Pages (from-to)	15-19
Number of pages	5
Journal	Cancer Journal
Volume	14
Issue number	1
DOIs	https://doi.org/10.1097/PPO.0b013e31816220b7
State	Published - Jan 2008

Keywords

Chemotherapy
Cytotoxic therapy
Hormone-refractory prostate cancer
Metastatic
Targeted therapy

ASJC Scopus subject areas

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1097/PPO.0b013e31816220b7

Cite this

@article{7030fea3b6914fb8adeb0ac9f1ad7c59,

title = "Promising novel cytotoxic agents and combinations in metastatic prostate cancer",

abstract = "Interest in investigating cytotoxic therapy has increased dramatically since a survival advantage was demonstrated in 2 phase III trials investigating docetaxel-based therapy in hormone-refractory prostate cancer. This result led to an expansion in research in this area with several ongoing trials evaluating docetaxel-based combinations and new cytotoxic agents.",

keywords = "Chemotherapy, Cytotoxic therapy, Hormone-refractory prostate cancer, Metastatic, Targeted therapy",

author = "Bradley, {Deborah A.} and Maha Hussain",

year = "2008",

month = jan,

doi = "10.1097/PPO.0b013e31816220b7",

language = "English (US)",

volume = "14",

pages = "15--19",

journal = "Cancer Journal",

issn = "1528-9117",

publisher = "Association Pour le Developpement de la Communication Cancerologique",

number = "1",

}

TY - JOUR

T1 - Promising novel cytotoxic agents and combinations in metastatic prostate cancer

AU - Bradley, Deborah A.

AU - Hussain, Maha

PY - 2008/1

Y1 - 2008/1

N2 - Interest in investigating cytotoxic therapy has increased dramatically since a survival advantage was demonstrated in 2 phase III trials investigating docetaxel-based therapy in hormone-refractory prostate cancer. This result led to an expansion in research in this area with several ongoing trials evaluating docetaxel-based combinations and new cytotoxic agents.

AB - Interest in investigating cytotoxic therapy has increased dramatically since a survival advantage was demonstrated in 2 phase III trials investigating docetaxel-based therapy in hormone-refractory prostate cancer. This result led to an expansion in research in this area with several ongoing trials evaluating docetaxel-based combinations and new cytotoxic agents.

KW - Chemotherapy

KW - Cytotoxic therapy

KW - Hormone-refractory prostate cancer

KW - Metastatic

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=43049154852&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=43049154852&partnerID=8YFLogxK

U2 - 10.1097/PPO.0b013e31816220b7

DO - 10.1097/PPO.0b013e31816220b7

M3 - Review article

C2 - 18303478

AN - SCOPUS:43049154852

SN - 1528-9117

VL - 14

SP - 15

EP - 19

JO - Cancer Journal

JF - Cancer Journal

IS - 1

ER -

Promising novel cytotoxic agents and combinations in metastatic prostate cancer

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this